ATE345775T1 - Zusammensetzungen zur verabreichung von arzneimittelkombinationen - Google Patents

Zusammensetzungen zur verabreichung von arzneimittelkombinationen

Info

Publication number
ATE345775T1
ATE345775T1 AT02766997T AT02766997T ATE345775T1 AT E345775 T1 ATE345775 T1 AT E345775T1 AT 02766997 T AT02766997 T AT 02766997T AT 02766997 T AT02766997 T AT 02766997T AT E345775 T1 ATE345775 T1 AT E345775T1
Authority
AT
Austria
Prior art keywords
compositions
administration
drug combinations
combinations
antagonistic
Prior art date
Application number
AT02766997T
Other languages
German (de)
English (en)
Inventor
Paul Tardi
Troy Harasym
Murray Webb
Clifford Shew
Lawrence Mayer
Marcel Bally
Andrew Janoff
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002383259A external-priority patent/CA2383259A1/en
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE345775T1 publication Critical patent/ATE345775T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02766997T 2001-10-03 2002-10-03 Zusammensetzungen zur verabreichung von arzneimittelkombinationen ATE345775T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32667101P 2001-10-03 2001-10-03
US34152901P 2001-12-17 2001-12-17
US35675902P 2002-02-15 2002-02-15
CA002383259A CA2383259A1 (en) 2002-04-23 2002-04-23 Synergistic compositions
US40198402P 2002-08-07 2002-08-07
US40873302P 2002-09-06 2002-09-06

Publications (1)

Publication Number Publication Date
ATE345775T1 true ATE345775T1 (de) 2006-12-15

Family

ID=32475852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766997T ATE345775T1 (de) 2001-10-03 2002-10-03 Zusammensetzungen zur verabreichung von arzneimittelkombinationen

Country Status (12)

Country Link
EP (2) EP1693052A1 (cg-RX-API-DMAC7.html)
JP (2) JP4778679B2 (cg-RX-API-DMAC7.html)
AT (1) ATE345775T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002331480B2 (cg-RX-API-DMAC7.html)
CA (1) CA2462369C (cg-RX-API-DMAC7.html)
CY (1) CY1105953T1 (cg-RX-API-DMAC7.html)
DE (1) DE60216305T2 (cg-RX-API-DMAC7.html)
DK (1) DK1432402T3 (cg-RX-API-DMAC7.html)
ES (1) ES2272768T3 (cg-RX-API-DMAC7.html)
IL (2) IL161214A (cg-RX-API-DMAC7.html)
PT (1) PT1432402E (cg-RX-API-DMAC7.html)
WO (1) WO2003028696A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
JP2006522026A (ja) * 2003-04-02 2006-09-28 セレーター ファーマスーティカルズ、インク． カンプトセシンとフルオロピリミジンとを組み合わせた組成物
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
US7846473B2 (en) 2004-06-01 2010-12-07 Terumo Kabushiki Kaisha Irinotecan preparation
WO2006014626A2 (en) 2004-07-19 2006-02-09 Celator Pharmaceuticals, Inc. Partuculate constructs for release of active agents
US20080213183A1 (en) * 2004-09-20 2008-09-04 Marcel Bally Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin
AU2005291807B2 (en) * 2004-10-06 2012-04-19 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
WO2008007113A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5815915B2 (ja) * 2005-10-11 2015-11-17 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム
AU2006306108B2 (en) * 2005-10-25 2012-10-04 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) * 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
JP2010519305A (ja) * 2007-02-26 2010-06-03 ウィスコンシン・アルムニ・リサーチ・ファウンデーション 併用薬物送達のためのポリマー性ミセル
US20110229572A1 (en) * 2007-08-16 2011-09-22 Biocompatibles Uk Limited Delivery of drug combinations
ES2535217T3 (es) 2007-11-28 2015-05-07 Celator Pharmaceuticals, Inc. Sistema mejorado de administración de taxano
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
WO2010043050A1 (en) 2008-10-16 2010-04-22 Celator Pharmaceuticals Corporation Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3265059A4 (en) * 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN107614019A (zh) 2015-03-09 2018-01-19 加利福尼亚大学董事会 用于组合抗癌疗法的聚合物‑药物结合物
EP3322404A4 (en) * 2015-07-15 2019-03-20 Celator Pharmaceuticals, Inc. IMPROVED NANOPARTICLE RELIEF SYSTEMS
CN105434437B (zh) * 2015-12-01 2018-03-02 山东大学 一种奥沙利铂和伊立替康类药物共载脂质体及其制备方法
CN106619509B (zh) * 2016-12-21 2020-02-18 山东大学 一种奥沙利铂和伊立替康共载载药脂肪乳及其制备方法
WO2021183318A2 (en) * 2020-03-09 2021-09-16 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US20240139175A1 (en) * 2020-12-23 2024-05-02 Cascade Prodrug Inc. Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL26210A (en) * 1965-08-02 1970-12-24 Merck & Co Inc Pharmaceutical compositions containing substituted sulphoxides
JP3213471B2 (ja) * 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
AU762078B2 (en) * 1999-03-24 2003-06-19 Secretary Of State For Defence, The Vaccine composition
EP1171118A2 (en) * 1999-04-09 2002-01-16 Jessie L.S. Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
CA2377385A1 (en) * 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
KR100591767B1 (ko) * 1999-09-09 2006-06-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀
AU7767200A (en) * 1999-10-14 2001-04-23 1170535 Ontario Inc. Liposome encapsulated silver salt compositions
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
ES2230268T3 (es) * 2000-02-10 2005-05-01 Liplasome Pharma A/S Sistema de liberacion de farmacos basados en lipidos.
JP2003527441A (ja) * 2000-03-22 2003-09-16 グラクソ グループ リミテッド 細胞周期を阻止する薬剤及び抗体を含む医薬

Also Published As

Publication number Publication date
IL188774A0 (en) 2008-04-13
JP4778679B2 (ja) 2011-09-21
WO2003028696A8 (en) 2006-09-08
IL161214A (en) 2008-06-05
PT1432402E (pt) 2007-02-28
DE60216305T2 (de) 2007-07-05
JP2005508920A (ja) 2005-04-07
DE60216305D1 (de) 2007-01-04
ES2272768T3 (es) 2007-05-01
WO2003028696A2 (en) 2003-04-10
WO2003028696A3 (en) 2003-07-31
DK1432402T3 (da) 2007-03-26
AU2002331480B2 (en) 2007-10-25
CA2462369C (en) 2009-12-22
EP1432402B1 (en) 2006-11-22
EP1432402A2 (en) 2004-06-30
CY1105953T1 (el) 2011-04-06
HK1065714A1 (en) 2005-03-04
EP1693052A1 (en) 2006-08-23
JP2010180210A (ja) 2010-08-19
JP4926256B2 (ja) 2012-05-09
CA2462369A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
WO2004093795A3 (en) Compositions for delivery of drug combinations
NZ527157A (en) Compositions for delivering bisphosphonates
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
TR200400295T2 (tr) Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi
MX2007002189A (es) Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
NO20026255L (no) Polymere micellesammensetninger
ATE433961T1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
MXPA05002814A (es) Formulacion para agentes lipofilicos.
GB0008269D0 (en) Combination chemotherapy
EP1496076A4 (en) HYDROPHILIC Y-BRANCH POLYMER DERIVATIVE AND METHOD OF MANUFACTURING THEREOF; ABOVE CONNECTED MEDICAL COMPOSITE
WO2003030934A3 (en) Cpg formulations and related methods
NO20061840L (no) Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
DK1392254T3 (da) Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
WO2005041936A3 (en) Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
ATE406161T1 (de) Kombination aus tenofovir, ritonavir und tmc114
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
WO2004090537A3 (en) Methods to individualize combination therapy
BR0011845A (pt) Complexo farmacêutico
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1432402

Country of ref document: EP